Alector, Inc. (NASDAQ:ALEC) Stock Has Consensus Target Price of $5.10

Shares of Alector, Inc. (NASDAQ:ALEC – Get Free Report) have earned an average rating of “Hold” from the seven analysts that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $5.10.

ALEC has been the topic of a number of research reports. Wells Fargo & Company initiated coverage on Alector in a report on Friday, November 13th. They set an “overweight” rating and a $7.00 price target on the stock. Morgan Stanley boosted their price target on Alector from $2.00 to $3.00 and gave the company an “underweight” rating in a research report on Tuesday, October 6th. Wall Street Zen raised Alector from a “hold” rating to a “buy” rating in a research note on Saturday, November 7th. UBS Group reaffirmed a “neutral” rating and set a $1.50 price objective on shares of Alector in a research report on Tuesday, October 6th. Finally, HC Wainwright initiated coverage on Alector in a research report on Friday, November 6th. They set a “strong-buy” rating for the company.

Get Our Latest Research Report on ALEC

Alector Stock Performance

NASDAQ ALEC opened at $2.34 on Friday. The firm has a market cap of $348.38 million, a PE ratio of 6.69, a P/E/G ratio of 0.16 and a beta of 0.61. Alector has a one year low of $1.09 and a one year high of $2.84. The firm’s fifty day moving average is $2.09 and its two-hundred day moving average is $2.06.

Alector (NASDAQ:ALEC – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $1.34. Alector had a net margin of 23.87% and a return on equity of 112.21%. The business had revenue of $162.87 million during the quarter, compared to analysts’ expectations of $2.19 million. Research analysts predict that Alector will post 0.68 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Arnon Rosenthal sold 72,606 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $2.66, for a total transaction of $193,131.96. Following the completion of the sale, the chief executive officer owned 2,294,600 shares in the company, valued at $6,103,636. This represents a 3.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Neil Berkley sold 29,251 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $2.66, for a total value of $77,807.66. Following the sale, the chief financial officer directly owned 350,649 shares of the company’s stock, valued at approximately $932,726.34. This represents a 7.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 111,303 shares of company stock worth $295,633. Corporate insiders own 8.30% of the company’s stock.

Hedge Funds Weigh In On Alector

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Alector in the 2nd quarter valued at $15,774,000. Nantahala Capital Management LLC purchased a new position in Alector during the 2nd quarter worth $8,679,399. Merck & Co. Inc. acquired a new stake in shares of Alector in the 2nd quarter worth $7,126,896. ADAR1 Capital Management LLC acquired a new stake in shares of Alector in the 2nd quarter worth $5,796,000. Finally, Spruce Street Capital LP acquired a new stake in shares of Alector in the 2nd quarter worth $4,223,147. 85.83% of the stock is owned by institutional investors and hedge funds.

About Alector

(Get Free Report)

Alector, Inc. is a biotechnology company based in South San Francisco, California, that develops investigational therapies for neurodegenerative diseases. Its research focuses on the role of the immune system in the brain and how immune pathways may be used to address disease processes. The company’s approach draws on human genetics and immunology to identify potential therapeutic targets. Its research has included programs targeting progranulin and TREM2, proteins associated with brain health and neurodegenerative disease.

Featured Stories

Analyst Recommendations for Alector (NASDAQ:ALEC)

Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.